SVB Wealth LLC Increases Position in IDEXX Laboratories, Inc. $IDXX

SVB Wealth LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,335 shares of the company’s stock after acquiring an additional 1,089 shares during the period. SVB Wealth LLC’s holdings in IDEXX Laboratories were worth $4,121,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Beacon Investment Advisory Services Inc. boosted its stake in IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of IDEXX Laboratories by 114.1% in the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares during the last quarter. Procyon Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth $1,966,000. Diversified Trust Co. raised its holdings in shares of IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares during the period. Finally, Mirabella Financial Services LLP boosted its position in shares of IDEXX Laboratories by 156.2% during the 3rd quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock valued at $2,806,000 after acquiring an additional 2,683 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 2.9%

Shares of NASDAQ:IDXX opened at $545.73 on Tuesday. The business has a 50-day moving average price of $560.88 and a 200 day moving average price of $618.83. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $43.05 billion, a price-to-earnings ratio of 40.19, a PEG ratio of 3.07 and a beta of 1.56. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on IDXX. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Citigroup began coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.